AngioDynamics: Awaiting Q2 Financial Insights and Expert Projections
Anticipating Second Quarter Financial Disclosures
AngioDynamics, Inc. (NASDAQ: ANGO) is scheduled to release its financial outcomes for the second quarter on Tuesday, January 6, 2026, prior to the commencement of trading. Investors and market watchers are keen to assess the company's latest performance metrics.
Analyst Predictions for the Upcoming Quarter
Industry analysts project that the Latham, New York-headquartered company will report a net loss of 10 cents per share for the quarter. This projection marks an increase in losses compared to the 4 cents per share loss recorded in the same period last year. Furthermore, the consensus revenue estimate for AngioDynamics stands at $76.43 million, an improvement from the $72.84 million generated in the prior year, as compiled by Benzinga Pro data.
Recent Corporate Updates and Stock Performance
On October 2, AngioDynamics revised its adjusted earnings per share outlook for the fiscal year 2026 upwards, signaling a positive shift in its financial expectations. Despite this optimistic revision, the company's shares experienced a modest dip of 1.8% on Friday, concluding the trading day at $12.87.
Expert Opinions on AngioDynamics Stock
Several financial experts have recently provided their assessments of AngioDynamics. William Plovanic, an analyst at Canaccord Genuity, reiterated a 'Buy' recommendation for the stock and elevated his price target from $17 to $18 on October 3, 2025. Plovanic boasts an impressive accuracy rate of 62% in his forecasts. Similarly, Yi Chen from HC Wainwright & Co. maintained a 'Buy' rating for the company with a price target of $16 on July 16, 2025, demonstrating an accuracy rate of 66%. These insights offer valuable perspectives for investors considering AngioDynamics.